New Delhi, April 9 -- India's pharmaceutical sector is likely to witness steady domestic growth but continued pressure in the US market in the fourth quarter of FY26, according to a report by Nuvama Institutional Equities.

The report noted that while the domestic business remains robust, overall profitability is expected to be impacted by margin pressures and weakness in exports.

"We reckon revenue/EBITDA/PAT of our coverage universe shall grow 10%/3%/-6% YoY," the report said, adding that "the aggregate EBITDA margin stands at 23.1% (-178bp YoY)."

Domestic demand is expected to remain a key growth driver, supported by strong performance across therapies such as cardiac, anti-diabetic and oncology.

"Domestic business to expand 12% YoY...